Drugs / HSK55718
Trials 3 · a red edge is where a trial was stopped
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 2 | NCT07533786 | May → Nov 2026 expected | — | Haisco Pharmaceutical Group Co., Ltd. | Recruiting | No outcome recorded |
| Phase 2 | NCT07551739 | Apr → Nov 2026 expected | — | Haisco Pharmaceutical Group Co., Ltd. | Not yet recruiting | No outcome recorded |
| Phase 2 | NCT07491146 | Mar → Oct 2026 expected | — | Yingyong Zhou,MD,PhD | Not yet recruiting | No outcome recorded |
Evidence & citations 2 cited values
Every value below carries the sentence it was read from. 3 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | HSK55718 | ClinicalTrials.gov intervention name — accepted as the source's own label NCT07491146 ↗ |
| Route | Intravenous | “given intravenously” NCT07491146 ↗ |